Last reviewed · How we verify
mycophenolate mofetil, methotrexate, cyclosporin
At a glance
| Generic name | mycophenolate mofetil, methotrexate, cyclosporin |
|---|---|
| Sponsor | Hospital Authority, Hong Kong |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Myalgia
- Insomnia
- Fatigue
- Headache
- Depression/anxiety
- Easy bruising
- Gastric reflux disease
- Swelling face
- Abdominal pain
- Fluid retension
- Muscular weekness
- Tremor
Key clinical trials
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (PHASE2)
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation (PHASE1, PHASE2)
- Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation (PHASE3)
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (PHASE4)
- Registry for Systemic Eczema Treatments
- GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: